These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17149863)

  • 41. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
    J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
    Devreux V; Wiesner J; Goeman JL; Van der Eycken J; Jomaa H; Van Calenbergh S
    J Med Chem; 2006 Apr; 49(8):2656-60. PubMed ID: 16610809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.
    Jahnke W; Rondeau JM; Cotesta S; Marzinzik A; Pellé X; Geiser M; Strauss A; Götte M; Bitsch F; Hemmig R; Henry C; Lehmann S; Glickman JF; Roddy TP; Stout SJ; Green JR
    Nat Chem Biol; 2010 Sep; 6(9):660-6. PubMed ID: 20711197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
    Szabo CM; Martin MB; Oldfield E
    J Med Chem; 2002 Jul; 45(14):2894-903. PubMed ID: 12086477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates.
    Cheng F; Oldfield E
    J Med Chem; 2004 Oct; 47(21):5149-58. PubMed ID: 15456258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
    Mukkamala D; No JH; Cass LM; Chang TK; Oldfield E
    J Med Chem; 2008 Dec; 51(24):7827-33. PubMed ID: 19053772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
    Mercklé L; de Andrés-Gómez A; Dick B; Cox RJ; Godfrey CR
    Chembiochem; 2005 Oct; 6(10):1866-74. PubMed ID: 16116659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
    Andaloussi M; Henriksson LM; Więckowska A; Lindh M; Björkelid C; Larsson AM; Suresh S; Iyer H; Srinivasa BR; Bergfors T; Unge T; Mowbray SL; Larhed M; Jones TA; Karlén A
    J Med Chem; 2011 Jul; 54(14):4964-76. PubMed ID: 21678907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.
    Kanimoto Y; Greenwood D
    Infection; 1987; 15(6):465-8. PubMed ID: 3325431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
    Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
    J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of bacterial isoprenoid synthesis by fosmidomycin, a phosphonic acid-containing antibiotic.
    Shigi Y
    J Antimicrob Chemother; 1989 Aug; 24(2):131-45. PubMed ID: 2676937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Untargeted Metabolomics To Ascertain Antibiotic Modes of Action.
    Vincent IM; Ehmann DE; Mills SD; Perros M; Barrett MP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2281-91. PubMed ID: 26833150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Matthiesen RA; Varney ML; Xu PC; Rier AS; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2018 Jan; 26(2):376-385. PubMed ID: 29248353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase.
    Zinglé C; Kuntz L; Tritsch D; Grosdemange-Billiard C; Rohmer M
    J Org Chem; 2010 May; 75(10):3203-7. PubMed ID: 20429517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Binding modes of reverse fosmidomycin analogs toward the antimalarial target IspC.
    Konzuch S; Umeda T; Held J; Hähn S; Brücher K; Lienau C; Behrendt CT; Gräwert T; Bacher A; Illarionov B; Fischer M; Mordmüller B; Tanaka N; Kurz T
    J Med Chem; 2014 Nov; 57(21):8827-38. PubMed ID: 25254502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The crystal structure of E.coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation.
    Mac Sweeney A; Lange R; Fernandes RP; Schulz H; Dale GE; Douangamath A; Proteau PJ; Oefner C
    J Mol Biol; 2005 Jan; 345(1):115-27. PubMed ID: 15567415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
    Gabelli SB; McLellan JS; Montalvetti A; Oldfield E; Docampo R; Amzel LM
    Proteins; 2006 Jan; 62(1):80-8. PubMed ID: 16288456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.